Seeking to change lives with next generation peptide therapeutics
FY 2023 Financial Results
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% ...
Zealand Pharma’s Obesity R&D Event
Phase 3 clinical trials to investigate survodutide for people living with obesity and overweight…
Upcoming events
Share Price
Our research
Applying our peptide platform to specialty disease areas to invent novel therapies.
Read more
Clinical pipeline
Advancing development programs in rare diseases and obesity. See our pipeline
About Zealand
Get a brief overview on Zealand and learn more about our company. Read more
Investors
Information for analysts, investors, and shareholders.
Read more